Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week

Published on 22/02/19 at 10:54am

Happy Friday! With the weekend within reach, check out our run-down of the top ten most popular articles on Pharmafile.com this week, including Keytruda's liver cancer failure, a "game-changing osteoasrthritis treatment, AstraZeneca's retirement of the MedImmune brand, and the promise of the first new asthma pill in two decades.

10. Poland and Slovenia included in US-EU mutual recognition agreement

Poland and Slovenia have been deemed capable of carrying out Good Manufacturing Practice (GMP) inspections at an equivalent level to the United States.

9. Keytruda falls short at Phase 3 in advanced liver cancer

MSD has revealed new Phase 3 data which indicates that its blockbuster immunotherapy Keytruda, in combination with best supportive care, failed to meet its primary endpoints in advanced liver cancer.

8. Lilly and Boehringer's Trajenta matches glimepiride in delaying cardiovascular events in type 2 diabetes patients

Boehringer Ingelheim and Eli Lilly’s Trajenta (linagliptin) met its primary endpoint in a recent trial, it has emerged, proving itself non-inferior to glimepiride in its ability to prolong the amount of time before the first occurrence of cardiovascular (CV) death, non-fatal myocardial infarction or non-fatal stroke in type 2 diabetes patients.

7. Intercept's NASH liver fibrosis drug shows promise at Phase 3

Intercept Pharmaceuticals has publicised promising new data on the efficacy of Ocaliva (obeticholic acid) in the treatment of liver fibrosis due to nonalcoholic steatohepatitis (NASH), sending the company’s shares up by 32%.

6. Pfizer overhauls Xeljanz study over concerns of increased risk of pulmonary embolism and death

Pfizer is set to overhaul the dosing groups in its ongoing study of Xeljanz (tofacitinib) after an evaluation from a Rheumatology Data Safety Monitoring Board (DSMB) highlighted safety concerns in the higher of the two doses.

5. "Game-changing" osteoarthritis drug receives £675k funding from Innovate UK

A novel and potentially “game-changing” oral therapy for the treatment of osteoarthritis (OA) has received a £675,000 cash injection from Innovate UK.

4. China to establish national rare disease network

China is set to establish a national collaborative network of hospitals for rare disease diagnosis and treatment to promote early detection and effective treatment of rare diseases.

3. Lundbeck and Otsuka's bipolar treatment fails Phase 3 trials due to unexpected placebo effect

Lundbeck and Otsuka’s treatment for bipolar disorder, Rexulti, failed to achieve its primary endpoint in two separate Phase 3 trials.

2. AstraZeneca to retire MedImmune brand amid restructuring

AstraZeneca is retiring the MedImmune brand as part of a restructuring that will see biologics integrated into two new R&D units.

1. First asthma pill in two decades could treat condition by reducing airway muscle

Researchers at the University of Leicester alongside colleagues in Vancouver, Canada, have revealed data that supports the efficacy of an investigational pill for the treatment of asthma. The oral, selective prostaglandin D2 receptor antagonist, known as Fevipiprant, is the first of its kind for two decades.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches